Long-Term Benefit of Sotorasib in Patients With KRAS G12C–Mutated Non–Small-Cell Lung Cancer: Plain Language Summary

Dy, Grace K., Govindan, Ramaswamy, Velcheti, Vamsidhar, Falchook, Gerald S., Italiano, Antoine, Wolf, Juergen, Sacher, Adrian G., Takahashi, Toshiaki, Ramalingam, Suresh S., Dooms, Christophe, Kim, Dong-Wan, Addeo, Alfredo, Desai, Jayesh, Schuler, Martin, Tomasini, Pascale, Hong, David S., Lito, Piro, Tran, Qui, Jones, Simon, Anderson, Abraham, Hindoyan, Antreas, Snyder, Wendy, Skoulidis, Ferdinandos, Li, Bob T.

doi:10.2217/fon-2023-0560

Description

This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer. CodeBreaK 100 specifically looked at patients with a particular change(mutation) in theIn total, 174 adults were treated with sotorasib.Results show the long-term benefit of sotorasib therapy for people with advanced

Journal

Future Oncology

Future Oncology 20 113-120, 2023-11-27

Informa UK Limited

Keywords

Details 詳細情報について

CRID: 1871146593221001472

DOI: 10.2217/fon-2023-0560

ISSN: 17448301; 14796694

PubMed: 38010044

Data Source

OpenAIRE

Export

Report a problem